Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

被引:14
|
作者
Topp, Max S. [1 ]
Stein, Anthony S. [2 ]
Goekbuget, Nicola [3 ]
Horst, Heinz-August [4 ]
Boissel, Nicolas [5 ]
Martinelli, Giovanni [6 ]
Kantarjian, Hagop [7 ]
Brueggemann, Monika [8 ]
Chen, Yuqi [9 ]
Zugmaier, Gerhard [10 ]
机构
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] City Hope Med Ctr, Gehr Leukemia Ctr, Duarte, CA USA
[3] Univ Klinikum, Med Klin Hamatol Onkol Rheumatol Infektiol 3, Frankfurt, Germany
[4] Univ Klinikum Schleswig Holstein, Klin Innere Med 2, Kiel, Germany
[5] Hop St Louis, Unite Hematol Adolescents & Jeunes Adultes, Paris, France
[6] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Sci Directorate, Meldola, FC, Italy
[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[8] Univ Klinikum Schleswig Holstein, Sekt Hamatol Spezialdiagnost, Klin Innere Med 2, Kiel, Germany
[9] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[10] Amgen Res Munich GmbH, Global Dev, Munich, Germany
来源
CANCER MEDICINE | 2021年 / 10卷 / 08期
关键词
acute lymphoblastic leukemia; BiTE® blinatumomab; salvage; stem cell transplant;
D O I
10.1002/cam4.3731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Blinatumomab is a BiTE(R) immuno-oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). To assess the efficacy and safety of blinatumomab as first salvage versus second or later salvage in patients with r/r BCP ALL. Patient-level pooled data were used for this analysis. In total, 532 adults with r/r BCP ALL treated with blinatumomab were included (first salvage, n = 165; second or later salvage, n = 367). Compared with patients who received blinatumomab as second or later salvage, those who received blinatumomab as first salvage had a longer median overall survival (OS; 10.4 vs. 5.7 months; HR, 1.58; 95% CI, 1.26-1.97; P < .001) and relapse-free survival (10.1 vs. 7.3 months; HR, 1.38; 95% CI, 0.98-1.93; P = .061), and higher rates of remission (n = 89 [54%] vs. n = 150 [41%]; odds ratio, 0.59; 95% CI, 0.41-0.85; P = .005), minimal residual disease response (n = 68 [41%] vs. n = 118 [32%]), and allogeneic hematopoietic stem cell transplant (alloHSCT) realization (n = 60 [36%] vs. n = 88 [24%]), and alloHSCT in continuous remission (n = 33 [20%] vs. n = 52 (14%]). In a subgroup analysis, there was no apparent effect of prior alloHSCT on median OS in either salvage group. The safety profile of blinatumomab was generally similar between the groups; however, cytokine release syndrome, febrile neutropenia, and infection were more frequent with second or later salvage than with first salvage. In this pooled analysis, the logistic regression analyses indicated greater benefit with blinatumomab as first salvage than as second or later salvage, as evident by the longer median OS, longer median RFS, and higher rates of remission. Overall, blinatumomab was beneficial as first salvage and as second or later salvage, but the effects were favorable as first salvage. Aims Materials & Methods Results Discussion Conclusion
引用
收藏
页码:2601 / 2610
页数:10
相关论文
共 50 条
  • [41] Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia
    Fuster, J. L.
    Bautista, F.
    Gonzalez, B.
    Fernandez, J. M.
    Rives, S.
    Dapena, J. L.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (09): : 1963 - 1966
  • [42] Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
    Martino, R
    Bellido, M
    Brunet, S
    Sureda, A
    Peyret, M
    Guárdia, R
    Altés, A
    Domingo-Albós, A
    Sierra, J
    BONE MARROW TRANSPLANTATION, 1998, 21 (10) : 1023 - 1027
  • [43] Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
    R Martino
    M Bellido
    S Brunet
    A Sureda
    M Peyret
    R Guárdia
    A Altés
    A Domingo-Albós
    J Sierra
    Bone Marrow Transplantation, 1998, 21 : 1023 - 1027
  • [44] Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
    Lee, Kum Ja
    Chow, Vivian
    Weissman, Ashley
    Tulpule, Sunil
    Aldoss, Ibrahim
    Akhtari, Mojtaba
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1301 - 1310
  • [45] Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission
    Urbino, Irene
    Lengline, Etienne
    Rabian, Florence
    Cerrano, Marco
    Kim, Rathana
    Chevillon, Florian
    Ferrero, Dario
    Sebert, Marie
    Dhedin, Nathalie
    Itzykson, Raphael
    Ades, Lionel
    Raffoux, Emmanuel
    Dombret, Herve
    Audisio, Ernesta
    Clappier, Emmanuelle
    Boissel, Nicolas
    BLOOD ADVANCES, 2024, 8 (10) : 2405 - 2409
  • [46] Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort
    Goto, Hiroaki
    Ogawa, Chitose
    Iida, Hiroatsu
    Horibe, Keizo
    Oh, Iekuni
    Takada, Satoru
    Maeda, Yoshinobu
    Minami, Hironobu
    Nakashima, Yasuhiro
    Morris, Joan D.
    Kormany, William
    Chen, Yuqi
    Miyamoto, Toshihiro
    ACTA HAEMATOLOGICA, 2022, 145 (06) : 592 - 602
  • [47] Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies
    Kantarjian, Hagop M.
    Stein, Anthony S.
    Bargou, Ralf C.
    Grande Garcia, Carlos
    Larson, Richard A.
    Stelljes, Matthias
    Goekbuget, Nicola
    Zugmaier, Gerhard
    Benjamin, Jonathan E.
    Zhang, Alicia
    Jia, Catherine
    Topp, Max S.
    CANCER, 2016, 122 (14) : 2178 - 2185
  • [48] Use of Blinatumomab for Relapse Therapy of B-Cell Precursor Acute Lymphoblastic Leukemia
    Pawinska-Wasikowska, K.
    Wyrobek, E.
    Klekawka, T.
    Luszawska-Kutrzeba, T.
    Garus, K.
    Pietrys, D.
    Zaniewska-Tekieli, A.
    Wieczorek, A.
    Balwierz, W.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S251 - S251
  • [49] Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia
    Ochs, Madeleine A.
    Marini, Bernard L.
    Benitez, Lydia L.
    Stump, Sarah E.
    Weis, Taylor M.
    Buhlinger, Kaitlyn M.
    Diaz, Thomas
    Reid, Justin H.
    Muluneh, Benyam
    Pettit, Kristen
    Burke, Patrick
    Bixby, Dale L.
    Perissinotti, Anthony J.
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1839 - 1848
  • [50] FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Bouchkouj, Najat
    Lin, Xue
    Wang, Xiaofei
    Przepiorka, Donna
    Xu, Zhenzhen
    Purohit-Sheth, Tejashri
    Theoret, Marc
    ONCOLOGIST, 2022, 27 (10): : 892 - 899